Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Oo

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|August 27, 2011
Does erythromycin have anti-inflammatory effects independent of its antimicrobial action?Charles Oo, Bharti Shah
Drug Discovery Today|May 1, 2021
Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemicCharles Oo, Barbara Ameer
Journal of Pharmaceutical Sciences|May 21, 2009
A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in ratsSoichi Itoh, Charles Oo
The American Journal of Medicine|June 21, 2016
Proposed Strategies for the Integration of Genomics in Primary CareCharles Oo, Robert J Noveck
Journal of Clinical Pharmacology|February 28, 2009
The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction studyCharles Oo, Ya-Chi Chen
Journal of Clinical Pharmacology|July 28, 2015
A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?Charles Oo, Lorraine M Rusch
Therapeutic Innovation & Regulatory Science|February 20, 2020
A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human DiseasesCharles Oo, Robert J Noveck
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 21, 2016
QT Correction: Using an Observed Regression Factor Applicable to a Population SubsetCharles Oo, Suraj S Kalbag
Expert Review of Clinical Pharmacology|March 3, 2016
Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug developmentCharles Oo, Suraj S Kalbag
Drug Discovery Today|September 10, 2019
Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspectiveCharles Oo, Sherwin K B Sy
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|August 27, 2011
Does erythromycin have anti-inflammatory effects independent of its antimicrobial action?Charles Oo, Bharti Shah
Drug Discovery Today|May 1, 2021
Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemicCharles Oo, Barbara Ameer
Journal of Pharmaceutical Sciences|May 21, 2009
A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in ratsSoichi Itoh, Charles Oo
The American Journal of Medicine|June 21, 2016
Proposed Strategies for the Integration of Genomics in Primary CareCharles Oo, Robert J Noveck
Journal of Clinical Pharmacology|February 28, 2009
The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction studyCharles Oo, Ya-Chi Chen
Journal of Clinical Pharmacology|July 28, 2015
A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?Charles Oo, Lorraine M Rusch
Therapeutic Innovation & Regulatory Science|February 20, 2020
A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human DiseasesCharles Oo, Robert J Noveck
Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques|April 21, 2016
QT Correction: Using an Observed Regression Factor Applicable to a Population SubsetCharles Oo, Suraj S Kalbag
Expert Review of Clinical Pharmacology|March 3, 2016
Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug developmentCharles Oo, Suraj S Kalbag
Drug Discovery Today|September 10, 2019
Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspectiveCharles Oo, Sherwin K B Sy
Pageof 4